je.st
news
Tag: acceptance
USNS Fall River JHSV completes acceptance trials
2014-08-05 01:00:00| Naval Technology
The US Navy's fourth Spearhead-class joint high-speed vessel (JHSV) USNS Fall River (JHSV 4) has completed navy acceptance trials testing and assessments in the Gulf of Mexico, paving the way for its delivery to the Military Sealift Command later thi
Tags: fall
river
acceptance
trials
DOE to award up to $4.5M to increase acceptance and deployment of alt fuel vehicles
2014-07-18 12:30:36| Green Car Congress
Tags: increase
acceptance
award
alt
Royal Australian Navys HMAS Anzac begins harbour acceptance trials
2014-07-16 01:00:00| Naval Technology
The Royal Australian Navy's Anzac-class frigate, HMAS Anzac, is set to start its harbour acceptance trials phase of its anti-ship missile defence (ASMD) upgrade.
Tags: acceptance
royal
begins
australian
Wärtsiläs two-stroke engines complete approval and acceptance tests
2014-06-18 01:00:00| Ship Technology
Wärtsilä's two-stroke engines, X72 and X62, designed to deliver fuel efficiency, provide reliability and reduce operational costs have successfully completed two different performance tests.
Tags: complete
tests
acceptance
approval
Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma
2014-05-06 14:40:00| Merck.com - Corporate News
Dateline City: BOSTON Priority Review Designation for MK-3475 BLA for Proposed Indication of Unresectable or Metastatic Melanoma in Patients Who Have Been Previously Treated with Ipilimumab Advancing New Phase 3 Studies with MK-3475 in Adjuvant Melanoma, Previously-Untreated Non-Small Cell Lung Cancer, Advanced Head & Neck and Bladder Cancers Data from Studies in Three Different Cancer Types to be presented at 2014 ASCO Annual Meeting Initiating Phase 1 Study with Investigational Anti-GITR Antibody (MK-4166) BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for MK-3475, Mercks investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab. Language: English Contact: MerckMedia:Ian McConnell, 973-901-5722Claire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
review
application
license
Sites : [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] next »